CliffBio
small molecule

FRUZAQLA

FRUQUINTINIB

Loss of exclusivitySeptember 2035latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameFRUZAQLA
Active ingredientFRUQUINTINIB
Strength5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusRX

Listed patents

PatentExpiresType
11046674September 2035use U-3753
10519142September 2035substance, product
7829574March 2032substance, product
8212033May 2028use U-3753

Regulatory exclusivity

CodeExpires
NCENovember 2028

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.